Xinqiang Han, MD
Clinical Cardiac Electrophysiology · Richmond, INNPI 1831287598
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $25,154 of the $31,586 with a category attached, or 79.6%. Abbott accounts for 86.4% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $13,683 and has fallen 96.3% since, to $504 in 2025.
Across 207 payments — averaging $152.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$27K
- Boston Scientific$2K
- Cardiofocus, Inc.$379
- Novartis$373
- AstraZeneca$153
- Gilead$136
- plus $975 from 21 others
Across 3 payments — averaging $855.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$3K
What the payments were for
- Consulting fees$25,15480%
- Travel & lodging$1,2594%
- Food & beverage$5,17316%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 86 | $27,294 |
| Boston Scientific | 29 | $2,276 |
| Cardiofocus, Inc. | 1 | $379 |
| Novartis | 24 | $373 |
| AstraZeneca | 6 | $153 |
| Gilead | 2 | $136 |
| Amgen | 9 | $126 |
| Merck | 7 | $123 |
| Pfizer | 5 | $84 |
| Sanofi-aventis U.S. LLC | 6 | $83 |
| Novo Nordisk | 4 | $76 |
| Medtronic(2 entities) | 3 | $70 |
| Actelion Pharmaceuticals US, Inc. | 3 | $52 |
| Johnson & Johnson | 3 | $45 |
| Scpharmaceuticals Inc. | 2 | $40 |
| Cardiva Medical, Inc. | 2 | $38 |
| Chiesi USA, Inc. | 2 | $35 |
| Lexicon Pharmaceuticals, Inc. | 2 | $32 |
| Altathera Pharmaceuticals LLC | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $18 |
| Bayer | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Philips North America LLC | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Impulse Dynamics (USA) Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Assurity Pacemaker$25,154
- WATCHMAN Access System$375
- AVEIR$213
- Ensite Cardiac Mapping System$169
- ENSITE PRECISION$163
- Farapulse$125
How this compares
$31,586 in reported general payments places this provider in the 65th percentile of 72 clinical cardiac electrophysiology providers in Indiana.
See all clinical cardiac electrophysiology providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 274 | $250,770 |
| EntrestoSacubitril/Valsartan | 42 | $47,866 |
| MultaqDronedarone Hcl | 18 | $36,025 |
| XareltoRivaroxaban | 46 | $34,405 |
| JardianceEmpagliflozin | 13 | $15,284 |
| FarxigaDapagliflozin Propanediol | 11 | $5,578 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 20 | $4,053 |
| SotalolSotalol Hcl | 175 | $3,677 |
| Amiodarone Hcl | 154 | $2,804 |
| Metoprolol Succinate | 177 | $1,973 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 93 | $1,682 |
| Flecainide Acetate | 38 | $1,635 |
| Metoprolol Tartrate | 132 | $736 |
| ClopidogrelClopidogrel Bisulfate | 72 | $633 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 30 | $482 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $84 | $250,770274 claims |
| NovartisEntresto | $373 | $47,86642 claims |
| Sanofi-aventis U.S. LLCMultaq | $83 | $36,02518 claims |
| Johnson & JohnsonXarelto | $45 | $34,40546 claims |
| AstraZenecaFarxiga | $153 | $5,57811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 72 clinical cardiac electrophysiology providers in Indiana.
Other clinical cardiac electrophysiology in Richmond
- Vuy LiRichmond$8K
- Eric PrystowskyIndianapolis$1.1M
- Chad BonhommeWestfield$925K
- Kevin TrulockIndianapolis$402K
- Sharath VipparthyIndianapolis$114K
- Jasen GilgeIndianapolis$93K
- Vincent KeatingIndianapolis$80K
- Christopher ReedIndianapolis$80K
- Marcelle StuckyIndianapolis$76K
- Joseph SzwedIndianapolis$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.